$-0.06 EPS Expected for BioLineRx Ltd. (BLRX)

July 14, 2018 - By Robert Sims

BioLineRx Ltd. (NASDAQ:BLRX) Logo

Analysts expect BioLineRx Ltd. (NASDAQ:BLRX) to report $-0.06 EPS on August, 14.They anticipate $0.01 EPS change or 20.00 % from last quarter’s $-0.05 EPS. After having $-0.06 EPS previously, BioLineRx Ltd.’s analysts see 0.00 % EPS growth. The stock increased 1.20% or $0.011 during the last trading session, reaching $0.931. About 261,392 shares traded. BioLineRx Ltd. (NASDAQ:BLRX) has risen 7.06% since July 14, 2017 and is uptrending. It has underperformed by 5.51% the S&P500.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Coverage

Among 2 analysts covering Biolinerx (NASDAQ:BLRX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Biolinerx has $4.0 highest and $3.0 lowest target. $3.50’s average target is 275.94% above currents $0.931 stock price. Biolinerx had 6 analyst reports since January 17, 2018 according to SRatingsIntel. The stock of BioLineRx Ltd. (NASDAQ:BLRX) earned “Buy” rating by H.C. Wainwright on Monday, June 18. The company was maintained on Wednesday, January 17 by H.C. Wainwright. Oppenheimer maintained BioLineRx Ltd. (NASDAQ:BLRX) on Tuesday, March 20 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Tuesday, May 22. The firm has “Buy” rating given on Tuesday, March 6 by H.C. Wainwright. Oppenheimer maintained it with “Buy” rating and $3.0 target in Tuesday, March 6 report.

BioLine Rx Ltd, a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company has market cap of $97.81 million. The Company’s development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a novel peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immunotherapy treatment in development for multiple solid tumors; and BL-5010, a customized, proprietary, pen-like applicator containing a novel, acidic, aqueous solution as a medical device for the non-surgical removal of benign skin lesions. It currently has negative earnings. The company's other therapeutic candidates comprise BL-1040, a novel, resorbable polymer solution for use in the prevention of ventricular remodeling that may occur in patients who have suffered an acute myocardial infarction; BL-9020, which is a novel monoclonal antibody treatment designed to prevent immune-mediated destruction of insulin-producing beta cells in the pancreas; BL-1210, a drug candidate intended for the treatment of liver fibrosis, primarily non- alcoholic steatohepatitis; BL-1220, an orally administered, novel composition of sodium alginate intended as a novel treatment for various liver failure conditions; and BL-1230, a cannabinoid receptor type 2 intended as a novel anti-inflammatory treatment for dry eye syndrome.

More recent BioLineRx Ltd. (NASDAQ:BLRX) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials” on July 09, 2018. Also Benzinga.com published the news titled: “Benzinga’s Daily Biotech Pulse: Hematology Conference In The Spotlight, Dr. Reddy To Launch Generic Opioid …” on June 15, 2018. Streetinsider.com‘s news article titled: “Maxim Group Maintains Bullish View on BioLineRx (BLRX) Amid Follow-Up Data for BL-8040” with publication date: June 18, 2018 was also an interesting one.

BioLineRx Ltd. (NASDAQ:BLRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: